• 专利标题:   New dual-affinity probe comprising surface binding moiety including inorganic surface binding peptide, and capture element, useful for detecting pathogen in sample.
  • 专利号:   WO2022051861-A1, CA3192327-A1
  • 发明人:   GREENE R C, BUERKI C, URTATIZ O
  • 专利权人:   GEMINA LAB LTD, GREENE R C, BUERKI C, URTATIZ O
  • 国际专利分类:   C07K016/00, C07K016/10, C07K016/12, C07K016/14, C07K019/00, G01N033/53, G01N033/543, G01N033/569
  • 专利详细信息:   WO2022051861-A1 17 Mar 2022 G01N-033/53 202227 Pages: 111 English
  • 申请详细信息:   WO2022051861-A1 WOCA051256 10 Sep 2021
  • 优先权号:   US076918P, US163695P, CA3192327

▎ 摘  要

NOVELTY - Dual-affinity probe comprising a surface binding moiety (SBM), where the SBM is optionally an inorganic surface binding peptide (ISBP), and a capture element (CE), optionally where the probe comprises at least one polypeptides, and where the ISBP and the CE are present on the same or different polypeptides is new. USE - The probe is useful for: detecting pathogen in a sample; and determining the presence of and/or quantifying an analyte in a test sample (all claimed). ADVANTAGE - The probe: has high specificity and high sensitivity; has high affinity to SARS-CoV-2 virus; and is more effective in analyte detection. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a system for the detection of a pathogen of known sequence, comprising a dual-affinity probe; (2) pathogen detection (M1) using the dual-affinity probe to analyse a medium for a pathogen; and (3) determining the presence of and/or quantifying an analyte in a test sample, comprising (a) contacting a test sample with a dual-affinity probe, where the dual-affinity probe comprises a surface binding moiety (SBM) or an inorganic surface binding polypeptide (ISBP) and an analyte-specific capture element (CE), under conditions and for a time sufficient for analyte present in the test sample to bind to the analyte specific capture element, thus forming complexes comprising the analyte bound to the dual-affinity probe, (b) determining the presence of and/or quantity of the complexes or analyte present in the complexes, (c) where the presence of the complexes or the analyte in the complexes indicates the presence of the analyte in the test sample, and the quantity of the complexes or the analyte in the complexes indicates the quantity of analyte present in the test sample, (d) thus determining the presence of and/or quantifying the analyte in the test sample.